Various Products / Diabetes

* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).

Online Inquiry

CAT# Product Name M.W Molecular Formula Inquiry
10-101-51 Protirelin 362.38 C16H22N6O4 Inquiry
A22002 (Pyr-1)-Apelin-13, human, bovine 1519.8 C69H108N21O16S Inquiry
B1605 Osteocalcin (1-49), human 5925.6 Inquiry
B1608 Osteocalcin (7-19) (human) 1407.6 Inquiry
B1610 Osteocalcin 30-43 Fragment 1663.8 Inquiry
C06004 Calcitonin (8-32) (salmon I) 2725.10 C119H198N36O37 Inquiry
C06005 Acetyl-(Asn30,Tyr32)-Calcitonin (8-32) (salmon I) 2890.25 C127H205N37O40 Inquiry
CAD-112 Adropin(34-76) (human, mouse, rat) 4499.88 C₁₉₀H₂₉₃N₅₅O₆₈S₂ Inquiry
CAD-114 Phylloseptin-L2 1595.95 C₇₆H₁₂₆N₁₈O₁₉ Inquiry
CPC1634 Carnosine 226.23 C9H14N4O3 Inquiry
G01027 Galanin (1-13)-Mastoparan 2809.44 Inquiry
I02007 Preptin, Human Pro-Insulin Growth Factor II (67-100), rat 3932.4 Inquiry
I02008 Preptin, Human Pro-Insulin Growth Factor II (67-100), mouse 3948.4 Inquiry
I02009 Preptin, Human Pro-Insulin Growth Factor II (96-129), human 4029.5 Inquiry
O03004 (Tyr38,Phe42.46)-Osteocalcin (38-49) (human) 1516.72 C73H101N19O17 Inquiry
O03006 (Glu13.17.20)-Osteocalcin (1-46) (mouse) 5114.75 C226H351N57O74S2 Inquiry
O03007 (Thr46)-Osteocalcin (45-49) (human) 519.60 C25H37N5O7 Inquiry
O1502 Osteocalcin (37-49) (human) 1589.77 Inquiry
O1504 6-FAM-(Glu13.17.20)-Osteocalcin (1-46) (mouse) 5473.05 Inquiry
O1506 Osteocalcin (45-49) (human) 581.67 Inquiry

Diabetes mellitus (DM) is a common endocrine and metabolic disease. Its basic pathological characteristics are absolute or relative insufficiency of insulin secretion, or insensitivity of peripheral tissue to insulin, which leads to a systemic disease characterized by glucose metabolism disorder, including fat and protein metabolism disorder. It is characterized by persistent hyperglycemia, positive urine glucose and decreased glucose tolerance. According to the World Health Organization, it is disclosed that one person in the world dies of diabetes every 10 seconds, and one person dies of diabetes every 30 seconds. Coupled with blindness, cardiovascular and cerebrovascular complications, diabetes has become a serious public health problem. Because of its wide range of side effects and other factors, the use of hypoglycemic drugs is limited in patients with diabetes. It is predicted that new antidiabetic drugs should have the following characteristics: novel mechanism of action, new therapeutic targets, no antagonism with existing traditional hypoglycemic drugs, preferably synergistic effect, oral administration and so on.

The research and development of anti-diabetic drugs

The research and development of antidiabetic drugs has been successful. Glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-IV (DPP-4) inhibitors and sodium-glucose co-transporter 2 (SGLT2) inhibitors are already on the market. G protein coupled receptor 119 (GPR119) agonists with new mechanisms are being developed. New therapeutic targets, such as 11β-hydroxysterol dehydrogenase 1 (11 β-HSD1) inhibitor, protein tyrosine phosphatase 1B (PTP1B) inhibitor and glucokinase (GK) agonist, have also made new breakthroughs in the study of new therapeutic targets such as antidiabetic drugs. The success of these studies will provide more methods for the treatment of diabetes in order to achieve better results.

Conclusion

With the deepening of various studies and the continuous improvement of clinical trials, more and more new hypoglycemic drugs have entered the pharmaceutical market. Attention should also be paid to the long-term safety and adverse reactions of these drugs. Before realizing its therapeutic potential, it is still necessary to further study its mechanism, and carry out long-term clinical observation and Meta-analysis on its safety and efficacy.

References

  1. Care, D. (2019). Standards of Medical Care in Diabetes 2019. Diabetes Care, 42, S81.
  2. Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., ... & Campbell, J. E. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature medicine, 21(1), 27.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Customer Support & Price Inquiry

Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!

 GsMTx4 is a synthetic and biologically active peptide toxin. Its molecular formula is C185H273N49O45S6, with the ...

 TC 14012 is a serum-stable derivative of the peptidomimetic T140, which is a cyclic peptide with the structure o ...

 Obtustatin isolated from the venom of the Vipera lebetina obtusa viper is a highly potent integrin α1β1 inhibito ...

 Acid-sensitive ion channels (ASICs) are a class of proton-gated ion channels belonging to the Degenerin/Epitheli ...

 Endothelin-1 (ET-1) is a vasoactive peptide containing 21 amino acids, which was first isolated from the culture ...

Quick Inquiry
×
Contact Us

USA

Address:

Tel: |

Email:

Germany

Address:

Copyright © 2024 Creative Peptides. All rights reserved.